X

By browsing this website, you accept the use of cookies, which helps us provide you with services and offers matching your centers of interest and compile visitor statistics. More on cookies

Up

Arkema in advanced review for investment project in Thiochemicals in the United States

- Press release
Corporate - Finance - Products
Arkema confirms a detailed investment review, with its partner Novus International, Inc., to double production capacities at Arkema’s Beaumont Thiochemicals site in the United States. This project will support the strong global growth in the animal nutrition market and further strengthens Arkema’s world leading position in high value-added sulfur derivatives.

Arkema is reviewing in detail, with its partner Novus, the doubling of production capacities at its Beaumont site in Texas to supply high value-added sulfur derivatives for the new methionine hydroxy analogue production unit announced by Novus at the end of 2017 at a site in Calhoun County, Texas.

This project would support the strong annual growth of the global demand for methionine, an essential amino acid for animal nutrition, which should reach 6% over the coming years.

 

Subject to a final decision on this investment, expected to be made at the end of 2018, the new units should come on stream by the summer of 2021.

 

Arkema thus confirms its technological leadership in thiochemical processes and its ambition to strengthen its world leading position in sulfur derivatives.

 

This project is part of Arkema’s long-term ambition announced by the Group at its 2017 Capital Markets Day and would represent a milestone in the Group’s future growth.

Contacts

Sophie FOUILLAT
Investor relations
Arie TAIEB
Investor relations
Gilles GALINIER
VP Communication
Arkema
Véronique OBRECHT
Corporate Press relations
Arkema
Contact